丹参酮ⅡA与白藜芦醇的复方药对青年大鼠峰值骨量的影响
|
摘要
目的研究丹参酮ⅡA和白藜芦醇的复方药对青年大鼠峰值骨量的影响,并探讨其可能的机制,为探索抗骨质疏松中药新药奠定基础。方法 1月龄雌性Wistar大鼠40只,使用随机数字表法分为丹参酮ⅡA组、白藜芦醇组、丹参酮ⅡA与白藜芦醇的复方组和正常对照组,每组10只。每两周称1次体重,每月用双能X射线骨密度仪检测全身骨密度;待用药组与对照组全身骨密度差异有统计学意义后,处死所有实验动物。测定右侧股骨和椎骨的离体骨密度;用AGX系列台式电子万能实验机检测股骨和椎骨生物力学性能;品红-苦味酸染色进行骨形态分析;酶联免疫吸附法检测血清抗酒石酸酸性磷酸酶5b和骨钙素的水平。结果各组间大鼠的体重差异无统计学意义(P>0.05);喂药1个月后全身骨密度差异无统计学意义(P>0.05),2个月后给药组全身骨密度均高于对照组,其中复方药物组大鼠全身骨密度(P=0.016)、股骨骨密度(P=0.001)和椎骨骨密度(P=0.034)、骨小梁数目(P=0.024)、骨小梁宽度(P=0.040)和面积(P=0.038)均显著提高,而骨小梁分离度显著降低(P=0.032);与对照组相比,复方药物组能显著提高大鼠血清中骨钙素的含量(P=0.033),同时显著降低血清中抗酒石酸酸性磷酸酶5b的含量(P=0.028)。结论丹参酮ⅡA与白藜芦醇的复方灌胃可有效提高大鼠骨密度及骨质量,且效果优于丹参酮ⅡA单体及白藜芦醇单体。这些结果对探索抗骨质疏松中药复方有重要启示。
Objective To study the effect of the compound medicine of tanshinone ⅡA and resveratrol on peak bone mass in growing rats and to explore its possible mechanism,so as to explore anti-osteoporosis mechanisms of new traditional Chinese medicine( TCM) drugs. Methods Totally 40 1-month-old female Wistar rats were randomly divided into tanshinone ⅡA group,resveratrol group,compound group( tanshinone ⅡA and resveratrol),and normal control group,with 10 rats in each group. Body weight was measured once every two weeks,and the whole body bone mineral density was measured with dual-energy X-ray monthly. When the whole-body bone mineral density became statistically significant between medication groups and control group,allanimals were sacrificed to determine the bone mineral density of vertebrae and right femoral bone. The biomechanical properties of femur and vertebrae were measured by AGS-X series universal test,then the bone morphology was analyzed with Fuchsin picric acid staining. Finally,the levels of tartrate-resistant acid phosphatase 5 b and osteocalcin were measured with enzyme-linked immunosorbent assay. Results The body weights were not statistically significant among all groups( P > 0. 05). The whole-body bone mineral density showed no significant difference( P > 0. 05) after feeding for 1 month; however,two months later,it was significantly different between medication groups and control group; in particular,the whole-body( P = 0. 016),femoral( P = 0. 001),and vertebral bone mineral density( P = 0. 034), bone trabecular number( P = 0. 024), thickness( P =0. 040),and area( P = 0. 038) were significantly increased in the compound group,along with the significantly decreased trabecular separation degree( P = 0. 032). Compared with the control group,the compound group had significantly increased osteocalcin( P = 0. 033) and tartrate-resistant acid phosphatase 5 b( P = 0. 028)levels in serum. Conclusion The compound of tanshinone Ⅱ A and resveratrol can improve the bone density and bone quality in rats, and such effect is higher than either tanshinone Ⅱ A monomer or resveratrol monomer.
Objective To study the effect of the compound medicine of tanshinone ⅡA and resveratrol on peak bone mass in growing rats and to explore its possible mechanism,so as to explore anti-osteoporosis mechanisms of new traditional Chinese medicine( TCM) drugs. Methods Totally 40 1-month-old female Wistar rats were randomly divided into tanshinone ⅡA group,resveratrol group,compound group( tanshinone ⅡA and resveratrol),and normal control group,with 10 rats in each group. Body weight was measured once every two weeks,and the whole body bone mineral density was measured with dual-energy X-ray monthly. When the whole-body bone mineral density became statistically significant between medication groups and control group,allanimals were sacrificed to determine the bone mineral density of vertebrae and right femoral bone. The biomechanical properties of femur and vertebrae were measured by AGS-X series universal test,then the bone morphology was analyzed with Fuchsin picric acid staining. Finally,the levels of tartrate-resistant acid phosphatase 5 b and osteocalcin were measured with enzyme-linked immunosorbent assay. Results The body weights were not statistically significant among all groups( P > 0. 05). The whole-body bone mineral density showed no significant difference( P > 0. 05) after feeding for 1 month; however,two months later,it was significantly different between medication groups and control group; in particular,the whole-body( P = 0. 016),femoral( P = 0. 001),and vertebral bone mineral density( P = 0. 034), bone trabecular number( P = 0. 024), thickness( P =0. 040),and area( P = 0. 038) were significantly increased in the compound group,along with the significantly decreased trabecular separation degree( P = 0. 032). Compared with the control group,the compound group had significantly increased osteocalcin( P = 0. 033) and tartrate-resistant acid phosphatase 5 b( P = 0. 028)levels in serum. Conclusion The compound of tanshinone Ⅱ A and resveratrol can improve the bone density and bone quality in rats, and such effect is higher than either tanshinone Ⅱ A monomer or resveratrol monomer.
引文
[1]Ohta H,Solanki J.Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan[J].Osteoporos Int,2015,26(3):849-863.DOI:10.1007/s00198-014-2940-x.
[2]徐东红,齐燕,李佩岚,等.骨质疏松症的药物治疗进展[J].医学理论与实践,2014,27(11):1428-1430.DOI:10.19381/j.issn.1001-7585.2014.11.013.
[3]Alvarez A,Kremer R,Weiss DR,et al.Response of postpoliomyelitis patients to bisphosphonate treatment[J].PM R,2010,2(12):1094-1103.DOI:10.1016/j.pmrj.2010.08.009.
[4]郭威.丹参酮ⅡA对大鼠骨髓间充质干细胞成骨分化影响的实验研究[D].锦州:辽宁医学院,2012.
[5]董瓅瑾,宋光明,孙静,等.白藜芦醇影响骨生长作用的研究进展[J].武警后勤学院学报(医学版),2013,22(2):149-152.DOI:10.3969/j.issn.2095-3720.2013.02.030.
[6]崔燎,吴铁,刘晓青,等.低剂量雌激素与中药联合用药有效防治大鼠去卵巢所致骨质丢失[J].中国骨质疏松杂志,2003,9(3):200-204.DOI:10.3969/j.issn.1006-7108.2003.03.004.
[7]Mardon J,Mathey J,Kati-Coulibaly S,et al.Influence of life long soy isoflavones consumption on bone mass in the rat[J].Exp Biol Med,2008,233(2):229-237.DOI:10.3181/0707-RM-202.
[8]Gautam AK,Bhargavan B,Tyagi AM,et al.Differential effects of formononetin and cladrin on osteoblast function,peak bone mass achievement and bioavaibility in rats[J].J Nutr Biochem,2011,22(4):318-327.DOI:10.1016/j.jnutbio.
[9]黄莉,刘允,魏秋实,等.补肾健脾化瘀方对去势大鼠股骨区域性骨矿含量和骨密度的影响[J].广东医学,2014,35(4):489-492.DOI:10.13820/j.cnki.gdyx.2014.04.001.
[10]刘爽,毕聪聪,孙伟明.补肾复方对去卵巢骨质疏松模型大鼠骨生物力学、骨微结构和骨代谢相关指标的影响[J].辽宁中医杂志,2016,43(10):2192-2194.DOI:10.13192/j.issn.1000-1719.2016.10.061.
[11]成魁,王鸣刚,陈克明,等.口服蛇床子素提高大鼠峰值骨量的研究[J].中国现代应用药学,2013,30(11):1170-1174.DOI:10.13748/j.cnki.issn1007-7693.2013.11.012.
[12]贾韦国.吸收与代谢后寡单体复合药物中药现代化的新尝试[J].中西医结合学报,2006,4(5):441-446.DOI:1672-1977(2006)05-0441-06.
[13]Elmarakby AA,Ibrahim AS,Faulkner J,et al.Tyrosine kinase inhibitor,genistein,reduces renal inflammation and injury in streptozotocin-induced diabetic mice[J].Vascul Pharmacol,2011,55(5-6):149-156.DOI:10.1016/j.vph.2011.07.007.
[14]成魁,葛宝丰,甄平,等.蛇床子素与金雀异黄酮对大鼠峰值骨量影响的比较研究[J].中国骨伤,2014,27(7):587-591.DOI:10.3969/j.issn.1003-0034.2014.07.013.
[2]徐东红,齐燕,李佩岚,等.骨质疏松症的药物治疗进展[J].医学理论与实践,2014,27(11):1428-1430.DOI:10.19381/j.issn.1001-7585.2014.11.013.
[3]Alvarez A,Kremer R,Weiss DR,et al.Response of postpoliomyelitis patients to bisphosphonate treatment[J].PM R,2010,2(12):1094-1103.DOI:10.1016/j.pmrj.2010.08.009.
[4]郭威.丹参酮ⅡA对大鼠骨髓间充质干细胞成骨分化影响的实验研究[D].锦州:辽宁医学院,2012.
[5]董瓅瑾,宋光明,孙静,等.白藜芦醇影响骨生长作用的研究进展[J].武警后勤学院学报(医学版),2013,22(2):149-152.DOI:10.3969/j.issn.2095-3720.2013.02.030.
[6]崔燎,吴铁,刘晓青,等.低剂量雌激素与中药联合用药有效防治大鼠去卵巢所致骨质丢失[J].中国骨质疏松杂志,2003,9(3):200-204.DOI:10.3969/j.issn.1006-7108.2003.03.004.
[7]Mardon J,Mathey J,Kati-Coulibaly S,et al.Influence of life long soy isoflavones consumption on bone mass in the rat[J].Exp Biol Med,2008,233(2):229-237.DOI:10.3181/0707-RM-202.
[8]Gautam AK,Bhargavan B,Tyagi AM,et al.Differential effects of formononetin and cladrin on osteoblast function,peak bone mass achievement and bioavaibility in rats[J].J Nutr Biochem,2011,22(4):318-327.DOI:10.1016/j.jnutbio.
[9]黄莉,刘允,魏秋实,等.补肾健脾化瘀方对去势大鼠股骨区域性骨矿含量和骨密度的影响[J].广东医学,2014,35(4):489-492.DOI:10.13820/j.cnki.gdyx.2014.04.001.
[10]刘爽,毕聪聪,孙伟明.补肾复方对去卵巢骨质疏松模型大鼠骨生物力学、骨微结构和骨代谢相关指标的影响[J].辽宁中医杂志,2016,43(10):2192-2194.DOI:10.13192/j.issn.1000-1719.2016.10.061.
[11]成魁,王鸣刚,陈克明,等.口服蛇床子素提高大鼠峰值骨量的研究[J].中国现代应用药学,2013,30(11):1170-1174.DOI:10.13748/j.cnki.issn1007-7693.2013.11.012.
[12]贾韦国.吸收与代谢后寡单体复合药物中药现代化的新尝试[J].中西医结合学报,2006,4(5):441-446.DOI:1672-1977(2006)05-0441-06.
[13]Elmarakby AA,Ibrahim AS,Faulkner J,et al.Tyrosine kinase inhibitor,genistein,reduces renal inflammation and injury in streptozotocin-induced diabetic mice[J].Vascul Pharmacol,2011,55(5-6):149-156.DOI:10.1016/j.vph.2011.07.007.
[14]成魁,葛宝丰,甄平,等.蛇床子素与金雀异黄酮对大鼠峰值骨量影响的比较研究[J].中国骨伤,2014,27(7):587-591.DOI:10.3969/j.issn.1003-0034.2014.07.013.